Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Redburn Partners Reinstates Neutral on Omnicom Group

Redburn Partners Reinstates Neutral on Omnicom Group

Redburn Partners analyst Bianca Dallal reinstates Omnicom Group (NYSE:OMC) with a Neutral.

byBenzinga Newsdesk

September 8, 2022

1 minute read

Redburn Partners analyst Bianca Dallal reinstates Omnicom Group (NYSE:OMC) with a Neutral.

Raymond James Maintains Outperform on MSCI, Lowers Price Target to $499

By Benzinga Newsdesk

October 17, 7:24 AM

Raymond James analyst Patrick O'Shaughnessy maintains MSCI (NYSE:MSCI) with a Outperform and lowers the price target from $510 to $499.

MSCI

News

Powerfleet Expands Personal Safety IoT Marketplace Through Partnership With ClickNow

By Benzinga Newsdesk

November 11, 10:15 AM

Powerfleet, Inc. (NASDAQ:PWFL), a global leader of Internet of Things (IoT) software-as-a-service (SaaS) solutions that optimize the performance of mobile assets and resources to unify business operations, has

PWFL

Deutsche Bank Maintains Buy on Colgate-Palmolive, Raises Price Target to $87

By Benzinga Newsdesk

December 6, 10:59 AM

Deutsche Bank analyst Steve Powers maintains Colgate-Palmolive (NYSE:CL) with a Buy and raises the price target from $85 to $87.

Citigroup Initiates Coverage On PTC Therapeutics with Buy Rating, Announces Price Target of $70

By Benzinga Newsdesk

September 1, 6:21 AM

Citigroup analyst David Lebowitz initiates coverage on PTC Therapeutics (NASDAQ:PTCT) with a Buy rating and announces Price Target of $70.

PTCT

Redburn Partners Reinstates Neutral on Omnicom Group

Related Posts

Raymond James Maintains Outperform on MSCI, Lowers Price Target to $499

Powerfleet Expands Personal Safety IoT Marketplace Through Partnership With ClickNow

Deutsche Bank Maintains Buy on Colgate-Palmolive, Raises Price Target to $87

Citigroup Initiates Coverage On PTC Therapeutics with Buy Rating, Announces Price Target of $70